Omega Fund Management

Latest statistics and disclosures from Omega Fund Management's latest quarterly 13F-HR filing:

  • Top 5 stock holdings are REPL, MORF, GOSS, ARQT, TBIO, and represent 78.34% of Omega Fund Management's stock portfolio.
  • Added to shares of these 3 stocks: ARQT (+$25.17M), BEAM (+$5.45M), CDTX.
  • Started 2 new stock positions in ARQT, BEAM.
  • Reduced shares in these 3 stocks: GOSS (-$18.71M), PRVL, EPIX.
  • Omega Fund Management was a net buyer of stock by $7.91M.
  • Omega Fund Management has $241.63M in assets under management (AUM), dropping by -23.08%.

Portfolio Holdings for Omega Fund Management

Companies in the Omega Fund Management portfolio as of the March 2020 quarterly 13F filing

Company (Ticker) Portfolio Weight Share Count Change in Shares Price
Replimune Group Inc (REPL) 21.86 5.32M 9.92
Morphic Hldg Inc Com (MORF) 18.04 2.97M 14.68
Gossamer Bio Inc (GOSS) 17.96 4.28M -30% 10.15
Arcutis Biotherapeutics (ARQT) 10.42 844.68k NEW 29.80
Translate Bio Inc (TBIO) 10.06 2.44M 9.97
Immunic Inc (IMUX) 3.43 1.37M 6.05
Paratek Pharmaceuticals (PRTK) 3.39 2.60M 3.15
Essa Pharma Inc (EPIX) 2.80 1.69M 4.00
Beam Therapeutics (BEAM) 2.26 302.82k NEW 18.00
Cidara Therapeutics Inc Common Stock Usd 0.0001 (CDTX) 2.06 2.01M +22% 2.48
Fibrogen (FGEN) 1.88 130.65k 34.75
Trevi Therapeutics Inc (TRVI) 1.72 1.26M 3.29
Prevail Therapeutics Ord (PRVL) 1.38 272.81k -59% 12.19
Jounce Therapeutics (JNCE) 1.04 529.97k 4.75
Obseva Sa (OBSV) 1.00 999.36k 2.41
Pieris Pharmaceuticals (PIRS) 0.71 750.74k 2.28

Past Filings by Omega Fund Management

View past SEC 13F filings by Omega Fund Management

View all filings